Well under 15% of differentiated thyroid carcinoma (DTC) is diagnosed at≤ 18 years of age.
The population is heterogenous and the differences between prepubertal children and …

Although differentiated thyroid cancer (DTC) is typically an indolent disease with a high rate
of cure, recurrence is common (15%–30% of patients), even in early-stage disease. These …

Detection of residual tissue after thyroidectomy for papillary or follicular thyroid carcinoma
may be performed using diagnostic imaging with either 123I or 131I. The former is often …

Context: Although commonly performed, data are lacking regarding efficacy and safety of
lymph node dissection (LND) for recurrent/persistent papillary thyroid cancer (PTC) …

Stunning of thyroid tissue by diagnostic activities of 131I has been described by some
investigators and refuted by others. The support both for and against stunning has at times …

When thyroid tissues exhibited concentrations of therapeutic 131I that appeared to be less
than that predicted by data from the preceding diagnostic 131I, the phenomenon was called …

Recent clinical and experimental data demonstrate that thyroid stunning is caused by
previous irradiation and may influence the efficacy of 131I radiation therapy of thyroid cancer …

Objective: Dosimetry studies have shown that activities of 131 I as small as 10-20 MBq may
cause a stunning effect. A result of this stunning effect may be a lower success rate of the …

Objectives The use of 123 I whole body scintigraphy (WBS) before 131 I radioiodine ablation
(RIA) of the post-surgical thyroid remnant in patients with papillary thyroid cancer (PTC) …

Context: Published studies of thyroid stunning due to preablation 131I scanning in the
treatment of differentiated thyroid cancer after thyroidectomy had shown inconsistent clinical …